[HTML][HTML] Recent advancements in 18F-labeled PSMA targeting PET radiopharmaceuticals
S Piron, J Verhoeven, C Vanhove, F De Vos - Nuclear Medicine and …, 2022 - Elsevier
Prostate specific membrane antigen (PSMA) is an attractive target for molecular imaging of
prostate cancer and several other solid tumors because of its overexpression in prostate …
prostate cancer and several other solid tumors because of its overexpression in prostate …
Validation of 18F-rhPSMA-7 and 18F-rhPSMA-7.3 PET imaging results with histopathology from salvage surgery in patients with biochemical recurrence of prostate …
M Kroenke, L Schweiger, T Horn, B Haller… - Journal of Nuclear …, 2022 - Soc Nuclear Med
18F-rhPSMA-7, and its single diastereoisomer form, 18F-rhPSMA-7.3, are prostate-specific
membrane antigen (PSMA)–targeting radiopharmaceuticals. Here, we investigated their …
membrane antigen (PSMA)–targeting radiopharmaceuticals. Here, we investigated their …
Patterns of prostate cancer recurrence after brachytherapy determined by prostate-specific membrane antigen–positron emission tomography and computed …
Purpose The aim of this study was to characterize the patterns of prostate cancer recurrence
after brachytherapy (BT) using 2-(3-[1-carboxy-5-([6-18 F-fluoropyridine-3-carbonyl]-amino) …
after brachytherapy (BT) using 2-(3-[1-carboxy-5-([6-18 F-fluoropyridine-3-carbonyl]-amino) …
Diagnostic performance of 18F-labeled PSMA PET/CT in patients with biochemical recurrence of prostate cancer: a systematic review and meta-analysis
YY Yang, ZM Liu, RC Peng - Acta Radiologica, 2023 - journals.sagepub.com
Background After initial treatment of prostate cancer, increases in prostate-specific antigen
(PSA) levels commonly signify potential relapse or metastasis. 18F-labeled prostate-specific …
(PSA) levels commonly signify potential relapse or metastasis. 18F-labeled prostate-specific …
Improved prediction of chemoresistance in patients with diffuse large B-cell lymphoma through a new interim positron emission tomography-computed tomography …
W Xie, MK Liu, XF Jiang, XD Gao, B Li, L Wang… - Acta …, 2021 - Taylor & Francis
Objectives The positron emission tomography (PET) could predict the prognosis of DLBCL
patients, but the exact procedure on interim PET (iPET) to determine chemoresistant patients …
patients, but the exact procedure on interim PET (iPET) to determine chemoresistant patients …
PSMA in Diagnostik und Therapie
CA Fink, E Mamlins, J Cardinale, S Körber… - PET/CT-Atlas …, 2024 - Springer
Das prostataspezifische Membranantigen (PSMA) ist ein transmembranöses Glykoprotein,
das in Prostatakarzinomzellen im Vergleich zu Normalgewebe bis zu 1000-fach …
das in Prostatakarzinomzellen im Vergleich zu Normalgewebe bis zu 1000-fach …